Acoramidis Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 356 mg
Reference Brands: Attruby(USA/EU), Beyonttra (UK)
Category:
Heart Disorder
Acoramidis is a first-in-class oral transthyretin (TTR) stabilizer designed for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. This rare and progressive heart condition can lead to heart failure and increased risk of cardiovascular death. Acoramidis works by stabilizing the TTR protein, preventing amyloid deposits in the heart, thereby reducing cardiovascular death and related hospitalizations.
Acoramidis is available in Tablet
and strengths such as 356 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Acoramidis is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Acoramidis can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing